Misplaced Pages

Nicofuranose

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Nicofuranose
Clinical data
ATC code
Identifiers
IUPAC name
  • 1,3,4,6-tetrakis-O-(pyridin-3-ylcarbonyl)-β-D-fructofuranose
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.035.789 Edit this at Wikidata
Chemical and physical data
FormulaC30H24N4O10
Molar mass600.540 g·mol
3D model (JSmol)
SMILES
  • C1=CC(=CN=C1)C(=O)OC2(((O2)(COC(=O)C3=CN=CC=C3)O)OC(=O)C4=CN=CC=C4)OC(=O)C5=CN=CC=C5
InChI
  • InChI=1S/C30H24N4O10/c35-26(19-5-1-9-31-13-19)40-17-23-24(42-28(37)21-7-3-11-33-15-21)25(43-29(38)22-8-4-12-34-16-22)30(39,44-23)18-41-27(36)20-6-2-10-32-14-20/h1-16,23-25,39H,17-18H2/t23-,24-,25+,30-/m1/s1
  • Key:FUWFSXZKBMCSKF-ZASNTINBSA-N
  (what is this?)  (verify)

Nicofuranose is a niacin derivative used as a hypolipidemic agent.

References

  1. Kopelevich VM, Gunar VI (1999). "Some approaches to the directed search for new drugs based on nicotinic acid". Pharm Chem J. 33 (4): 177–187. doi:10.1007/BF02509934.
Lipid-lowering agents (C10)
GI tract
Cholesterol absorption inhibitors, NPC1L1
Bile acid sequestrants/resins (LDL)
Liver
Statins (HMG-CoA reductase, LDL)
Niacin and derivatives (HDL and LDL)
MTTP inhibitors (VLDL)
ATP citrate lyase inhibitors (LDL)
Thyromimetics (VLDL)
Blood vessels
PPAR agonists (LDL)
Fibrates
Others
CETP inhibitors (HDL)
PCSK9 inhibitors (LDL)
ANGPTL3 inhibitors (LDL/HDL)
Combinations
Other


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

Categories: